



Astec LifeSciences Ltd.

**Date:** 29<sup>th</sup> July, 2024

To,  
**BSE Limited**  
P. J. Towers, Dalal Street, Fort  
Mumbai – 400 001

**Ref.:** BSE Scrip Code No. “533138”

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, Bandra - Kurla Complex,  
Bandra (East), Mumbai-400 051

**Ref.:** “ASTEC”

**Debt Segment NSE:**  
NCD-ASTEC-ISIN: INE563J08015

**Sub.: Press Release**

The Board of Directors of Astec LifeSciences Limited (“the Company”), at its Meeting held on **Monday, 29<sup>th</sup> July, 2024**, has approved the Unaudited Financial Results (both Standalone and Consolidated) as per Indian Accounting Standards (IND AS) for the Quarter ended 30<sup>th</sup> June, 2024.

We enclose a copy of the Press Release and the same is being placed on the website of the Company.

Please take the above information on your records.

Thanking you,

Yours sincerely,

**For Astec LifeSciences Limited**

**Tejashree Pradhan**  
**Company Secretary & Compliance Officer**  
**(FCS 7167)**

**Encl.: As Above**



Regd. Office :  
“Godrej One”, 3<sup>rd</sup> Floor,  
Pirojshanagar, Eastern Express Highway,  
Vikhroli (East), Mumbai - 400079,  
Maharashtra, India  
Telephone No. : 022-25188010  
Fax No. : 022-22618289  
Email id : astecinfo@godrejastec.com  
Website : www.godrejastec.com  
CIN : L99999MH1994PLC076236

## ASTEC LIFESCIENCES LIMITED

“Godrej One”, 3<sup>rd</sup> Floor, Pirojshanagar, Eastern Express Highway, Vikhroli (E), Mumbai-400079, India

CIN: L99999MH1994PLC076236

### PRESS RELEASE

**Mumbai, July 29, 2024:** Astec LifeSciences Limited (“Astec”) has today announced its financial results for the first quarter ended June 30, 2024

### FINANCIAL OVERVIEW

#### Q1FY25 Financial Summary

- Company reported consolidated total income of Rs. 70.3 crore in Q1FY25 as compared to Rs. 144.6 crore in Q1FY24
- Company reported consolidated EBITDA loss of Rs. 45.3 crore in Q1FY25 as compared to profit of Rs. 4.8 crore in the same period last year

### HIGHLIGHTS OF FINANCIAL PERFORMANCE (Q1FY25)

(Rs. in crore)

Particulars	Consolidated Quarterly		
	Q1FY25	Q1FY24	% Change
Total Income	70.3	144.6	-51.0%
Earnings before depreciation, interest and taxes (EBITDA)	-45.3	4.8	NM
Profit Before Tax (PBT)	-61.6	-11.0	NM
Net Profit after tax (PAT)	-39.7	-8.2	NM

### CHAIRMAN’S COMMENTS

**Commenting on the performance, Mr. N B Godrej, Chairman, Astec LifeSciences Limited, said:**

Astec continued to face pricing and demand headwinds in the enterprise products on account of de-stocking of the inventory across key markets. Challenging external environment necessitated write down of inventory which also significantly impacted the margins of the enterprise portfolio. Also, global logistics issues resulted in delay in receipt of essential raw materials for our Contract Manufacturing (CDMO) product which resulted in deferral of volumes. This unfortunate situation further compressed overall profit margins.

Particulars (₹ Crore)	Consolidated Quarterly		
	Q1FY25	Q1FY24	% Change
<b>Segment Breakdown</b>			
Enterprise	40.0	57.7	-30.6%
Contract Manufacturing	29.4	85.1	-65.5%
<b>Geography Breakdown</b>			
Exports	31.0	95.1	-67.4%
Domestic	38.4	47.7	-19.6%

- ENDS -

### About Astec LifeSciences Limited

Astec LifeSciences Limited (Astec) was incorporated in 1994 and is engaged in the manufacturing of agrochemical active ingredients (technical), bulk, formulations and intermediate products. Astec has a healthy sales mix of both exports and domestic sales. Our exports are to over 17 countries including the United States and countries across Europe, West Asia, South East Asia and Latin America and Africa.

For more information on the Company, please log on to [www.astecsl.com](http://www.astecsl.com)

For further information, please contact:

S. Varadaraj  
Godrej Agrovet Limited  
Email: [s.varadaraj@godrejagrovvet.com](mailto:s.varadaraj@godrejagrovvet.com)  
Tel No.: +91 22 2519 4864

Gaurang Chotalia  
Investor Relations  
Email: [gavlinvestors@godrejagrovvet.com](mailto:gavlinvestors@godrejagrovvet.com) / [gaurang.chotalia@godrejagrovvet.com](mailto:gaurang.chotalia@godrejagrovvet.com)  
Tel No.: +91 22 2519 4646

*Disclaimer: "Some of the statements in this communication may be 'forward looking statements' within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Company's operations include changes in industry structure, significant changes in political and economic environment in India and overseas, tax laws, import duties, litigation and labour relations."*